Kira Rupprecht brings substantial U.S. commercialization and product launch experience

3 May 2021 – (Birkerod, Denmark and Los Angeles, Calif.) – The Board of Directors of Reapplix, a company specializing in the biological treatment and management of diabetic foot ulcers, has appointed Kira Rupprecht as its new Chief Executive Officer, effective immediately. She will focus on expanding access to the company’s innovative 3C Patch® System, a biological wound therapy product made entirely from the patient’s own blood, in the U.S. and other priority markets around the world.

Diabetic foot ulcers are a major global health concern, as the number of people worldwide with diabetes has nearly quadrupled in the past 40 years. Today, approximately one in four people with the disease risk developing a foot ulcer. Twenty percent of those cases require amputation within a year.

Reapplix has an important mission to improve the quality of life for people who suffer from diabetes,” said Reapplix Board Chairman Richard Twomey. “The company is at a pivotal moment, and Kira brings the right mix of qualities to lead it through its next phase of growth. She brings a global perspective and proven track record commercializing medical devices and pharmaceuticals in the strategic North American market.

Reapplix is poised for tremendous growth in North America,” Rupprecht said. “The 3C Patch® is a novel, cost-effective, personalized wound treatment product and the only actively marketed one available in the U.S. in its category. The recent National Coverage Determination from the Centers for Medicare and Medicaid Services means we can accelerate its adoption and help more people overcome the debilitating effects of diabetes. I’m excited to join Reapplix and work with my colleagues in Denmark and the U.S. to achieve these ambitious goals.

Rupprecht joins Reapplix from Urgo Medical, where she successfully introduced new wound care growth platforms as Head of Global Marketing and a member of the global management board. Under her leadership, Urgo Medical grew to become the second-largest advanced wound care company in Europe. Most recently, she was the General Manager of Canada at Urgo Medical North America, where she was charged with introducing Urgo Medical’s innovations to the Canadian market.

Prior to her tenure at Urgo Medical, Rupprecht held strategic marketing roles at Allergan and Johnson & Johnson in the U.S. and Belgium. She has an MBA from Harvard Business School and a BA in economics and international relations from Brown University.


Richard Twomey, Chairman of the Board
+46 73 950 36 60


Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. The patented 3CPatch® System is an innovative, evidence-based biological wound therapy made entirely from the patient’s own blood – nothing else. Headquartered in Denmark, with a dedicated sales and distribution team in the United States, Reapplix is poised for commercial launch with a particular focus on the U.S. market.

Every wound is personal.